Treatment of recurrent metastatic colon cancer in the age of modern adjuvant therapy

Carla Kurkjian, Anthony J. Murgo, Shivaani Kummar

Research output: Contribution to journalReview articlepeer-review

2 Scopus citations


The treatment of patients with metastatic colon cancer has evolved tremendously over the past 10 years, with improved overall survival (OS) rates as a result of the advent of several important agents. Following the results of important adjuvant trials, the incorporation of oxaliplatin into the adjuvant setting has significantly increased the disease-free survival and OS rates in patients who undergo curative resection. However, still a significant number of patients will present with recurrent disease after being treated with oxaliplatin-containing chemotherapy regimens. Herein, we present approaches to the chemotherapeutic management of such patients with a review of the literature.

Original languageEnglish (US)
Pages (from-to)321-324
Number of pages4
JournalClinical Colorectal Cancer
Issue number5
StatePublished - Sep 2008
Externally publishedYes


  • Metastasis
  • Oxaliplatin
  • Platinum resistance
  • Recurrence

ASJC Scopus subject areas

  • Oncology
  • Gastroenterology


Dive into the research topics of 'Treatment of recurrent metastatic colon cancer in the age of modern adjuvant therapy'. Together they form a unique fingerprint.

Cite this